Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

work behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 130,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor StatementThis press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, that the strategic decision to add a direct sales force to focus on government and military accounts will continue to produce quarter-over-quarter sales growth; the opportunities to capture market presence based on anticipated study results; the expected results from the Company's clinical studies; the expectation of receiving another issued patent in the near term; the potential for the Company's patent strategy to be a barrier to competition; the potential for entering into new placenta recovery contracts that will meet the Company's future demand for placental tissue; the revenue goals for 2013; the growth in use of EpiFix® allografts, the continued increase in VA and government
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... N.J. , Dec. 15, 2014   Regeneron ... and NYSE: SNY) are collaborating with nationally-recognized patient and ... , an awareness program that will gauge how much ... associated with high LDL-C (bad cholesterol).  American adults are ... take a brief poll and answer a few key ...
(Date:12/15/2014)... , Dec. 15, 2014   DaVita HealthCare ... of the nation,s largest and most innovative health ... business units, DaVita Clinical Research  (DCR) and  HealthCare ... further expand its extensive clinical research and data ... disease (CKD) and end-stage renal disease (ESRD), as ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Sept. 22, 2011 Pain can affect anyone regardless ... have difficulty getting adequate pain care. Women, certain ethnic ... to be denied appropriate pain treatment.(1),(2) In the ... Purdue Pharma L.P. for pain management advocacy, offers new ...
... Sept. 22, 2011 Leaders from government, industry, academia, ... one of the most pressing health challenges we face: ... of new antibiotics to fight them.  The conference, "Reviving ... Innovation," is organized by the Pew Health Group, the ...
Cached Medicine Technology:In The Face of Pain® Offers New Tools and Resources to Patients, Caregivers and Healthcare Professionals Advocating for Better Pain Care 2In The Face of Pain® Offers New Tools and Resources to Patients, Caregivers and Healthcare Professionals Advocating for Better Pain Care 3Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs 2Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter , ... been believed to improve overall health, but a growing body ... heart, a new review finds. In fact, the benefits ... walking, said lead researcher Paula Chu, a doctoral candidate at ... of 37 clinical trials, found that people randomly assigned to ...
(Date:12/15/2014)... CARSON CITY, NV (PRWEB) December 15, 2014 ... new powerhouse company, JM Ocean Avenue. JM Ocean ... technology of the Veretekk online automated marketing system. ... by the June 2014 merger of Ocean Avenue and ... a more than $2 Billion per year company. , ...
(Date:12/15/2014)... MD (PRWEB) December 15, 2014 ... services today released “ Social Media Cheat Sheets ,” ... a community that drives results on the top ten ... marketing program. It helps drive awareness, engagement, and customer ... For marketers to make an impact on new networks ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in ... is contributing to the growth in the global audiological market. ... hearing loss and balance disorders are known as audiological devices. ... and amplifier. The global market is expected to grow at ... from 2014 to 2019. Some of the factors which are ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... with a history of severe milk allergy can safely drink ... research led by the Johns Hopkins Children,s Center and published ... of Allergy and Clinical Immunology . Investigators followed up ... earlier Hopkins Children,s-led study published in 2008 in which patients ...
... , NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: ... that identifies, acquires, and develops novel drug targets that ... Whiteman as its Chief Executive Officer. , Mr. Whiteman, ... London School of Economics . He will provide ...
... , Miami ... Area , , ... today to participating in a conspiracy to defraud the Medicare program of ... Division, U.S. Attorney Terrence Berg of the Eastern District of Michigan and ...
... , HATBORO, Pa., Aug. 18 ... IFLG ), a leading technology provider of enterprise ... that it has successfully achieved Motorola,s Enterprise Mobility Validation for ... Controller (MDC), InfoLogix,s innovative application platform for mobile ...
... , MOUNT PROSPECT, Ill., Aug. 18 The ... KnujOn for spotlighting the exploitation of search engines, advertising programs ... Prescription Drug Sponsored Search Results," released on August 18, 2009, ... Yahoo!,s online advertising program. , , ...
... , PRINCETON, N.J., Aug. 18 Covance (NYSE: ... with Merck to provide a broad array of genomics analysis services ... Gene Expression Laboratory. Effective August 17, 2009, Covance assumed control ... , About Covance , Covance, with ...
Cached Medicine News:Health News:Milk is safe, even encouraged, for some children after treatment for milk allergy 2Health News:GENova names Aaron Whiteman as CEO 2Health News:GENova names Aaron Whiteman as CEO 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 2Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 4Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 2Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 3Health News:NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets 2Health News:Covance and Merck & Co., Inc. Finalize Strategic Agreement 2
... Forms strong flexible gels for ... clarifier: mixture of wide range ... water 10 mg/mL, clear, faintly ... molecular biology MP: 90 °C ...
Inquire...
Inquire...
... Melt), A low temperature agarose for ... , Optimal for in-gel restriction digestion/ligation and ... very manageable clear gel that provides excellent ... approximately 65°C and remains fluid at 37°C ...
Medicine Products: